The Computerized Multiphasic Interactive
Neurocognitive DualDisplay™ System
(CMINDS®) is a next-generation neurocognitive and behavioral
assessment system that is uniquely defined by a DualDisplay™
approach that integrates rather than replaces an Examiner in the
process of evaluation. This architecture affords advanced capabilities
especially relevant for assessment of people who require ongoing assistance to
understand and complete testing.
CMINDS® provides a multimedia-capable platform that features digitally recorded human-voice instructions, detailed report
generation, integrated data management utilities and integrated examiner training modules for certification-contingent access control.
Interactive DualDisplay™ Architecture
CMINDS® is distinguished from all other computerized testing platforms by it's DualDisplay™ architecture
that supports two independent monitors on a single computer. This side-by-side configuration enables the Examiner
to closely monitor, guide, and interact with the subject in real time.
Learn More>>
|
Over 20 Test Instruments on One Platform
CMINDS® hosts an exceptionally wide range of cognitive and behavioral instruments, extending from tests
designed for detecting subtle developmental disorders to tests specifically designed for detecting and
characterizing specific disorders. Learn More>>
|
Flexible Battery Designer Utility
The CMINDS® Battery Designer Utility allows for greater flexibility in the sequencing of assessments
across multiple visits. Learn More>>
|
Perception Response Evaluation (PRE)
The CMINDS® Perception-Response Evaluation (PRE) is a brief test utilized to evaluate a subject’s
ability to perceive and respond to the auditory and visual tasks involved in the administration of a CMINDS®
battery, as well as a means of orienting the subject to CMINDS®.
Learn More>>
|
CMINDS® Test Design and Structure
CMINDS® tests are designed to achieve nearly identical face validity and structure in relation to their
antecedent, paper-based counterparts. Learn More>>
|
CMINDS® Reporting & Data Extraction Utilities
The CMINDS® Report Generation Module (RGM) was developed to provide optimized, flexible data reporting and
eliminate case report form (CRF) generation for clinical trials. Besides generation of comprehensive reports,
CMINDS® provides a flexible Data Extraction Utility to aid data export for further analysis.
Learn More>>
|
CMINDS® MATRICS™ - Equivalent Battery
CMINDS® hosts construct-equivalent computerized versions of the neurocognitive assessment instruments
constituting the MATRICS™ Consensus Cognitive Battery (MCCB™).
Learn More>>
|
Computerized Alzheimer's Disease Assessment and Characterization
NeuroComp has developed an enterprise-scale, computerized solution that integrates all requisite elements
for comprehensive AD characterization. Learn More>>
|
Electronic Response Capture
The Advanced Cognitive Assessment Platform (ACAP) is a hardware device designed specifically to serve as a
secondary display device for the CMINDS® dual monitor configuration. The ACAP integrates all necessary peripherals,
offering comprehensive electronic data capture for a range of complex behavioral responses,
such as verbal report, bilateral reaction time, direct voice capture, and digital graphic entry (electronic pen)
without keyboard or mouse entry. Learn More>>
|
Simplified Test Administration: PathLok™
PathLok™ Operation ensures that individual tests comprising a battery are automatically sequenced according to
the requirements of the resident protocol, thus reducing the potential for examiner errors in test administration. Learn More>>
|
Secure Data Storage and Transmission
CMINDS® utilizes DataSafe™, a comprehensive schema for ensuring that human subjects' data is protected from unauthorized access or unintended loss due to local hard disk "crash" or accidental deletion.
Learn More>>
|
Comprehensive Regulatory Compliance
By design, CMINDS® fully complies with all applicable regulatory agency requirements regarding the collection
and management of clinical data. Learn More>>
|
CMINDS® Publications
CMINDS® has
been utilized in Phase I, II & III clinical trials, as well as
investigator-initiated studies, at over 100 leading institutions throughout the
U.S., Canada and South America over the past 11 years.
The development of CMINDS® was funded by the National
Institute of Mental Health (NIMH)* and the National Institute on Aging (NIA)**
to provide efficient computerized versions of commonly applied, established
tests, as opposed to unique or proprietary designs.
Learn More>>
|